Literature DB >> 21317286

BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling.

Lisa Polzien1, Angela Baljuls, Marco Albrecht, Mirko Hekman, Ulf R Rapp.   

Abstract

BAD (Bcl-2 antagonist of cell death) belongs to the proapoptotic BH3-only subfamily of Bcl-2 proteins. Physiological activity of BAD is highly controlled by phosphorylation. To further analyze the regulation of BAD function, we investigated the role of recently identified phosphorylation sites on BAD-mediated apoptosis. We found that in contrast to the N-terminal phosphorylation sites, the serines 124 and 134 act in an antiapoptotic manner because the replacement by alanine led to enhanced cell death. Our results further indicate that RAF kinases represent, besides PAK1, BAD serine 134 phosphorylating kinases. Importantly, in the presence of wild type BAD, co-expression of survival kinases, such as RAF and PAK1, leads to a strongly increased proliferation, whereas substitution of serine 134 by alanine abolishes this process. Furthermore, we identified BAD serine 134 to be strongly involved in survival signaling of B-RAF-V600E-containing tumor cells and found that phosphorylation of BAD at this residue is critical for efficient proliferation in these cells. Collectively, our findings provide new insights into the regulation of BAD function by phosphorylation and its role in cancer signaling.
© 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317286      PMCID: PMC3093868          DOI: 10.1074/jbc.M110.177345

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Protein kinase CK2 phosphorylates BAD at threonine-117.

Authors:  Susanne Klumpp; Anette Mäurer; Yuan Zhu; Dagmar Aichele; Lorenzo A Pinna; Josef Krieglstein
Journal:  Neurochem Int       Date:  2004-10       Impact factor: 3.921

Review 2.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 3.  The BCL-2 protein family: opposing activities that mediate cell death.

Authors:  Richard J Youle; Andreas Strasser
Journal:  Nat Rev Mol Cell Biol       Date:  2008-01       Impact factor: 94.444

Review 4.  Ras oncogenes and their downstream targets.

Authors:  Krishnaraj Rajalingam; Ralf Schreck; Ulf R Rapp; Stefan Albert
Journal:  Biochim Biophys Acta       Date:  2007-01-28

Review 5.  Raf kinases: oncogenesis and drug discovery.

Authors:  Ralf Schreck; Ulf R Rapp
Journal:  Int J Cancer       Date:  2006-11-15       Impact factor: 7.396

6.  Reversible membrane interaction of BAD requires two C-terminal lipid binding domains in conjunction with 14-3-3 protein binding.

Authors:  Mirko Hekman; Stefan Albert; Antoine Galmiche; Ulrike E E Rennefahrt; Jochen Fueller; Andreas Fischer; Dirk Puehringer; Stefan Wiese; Ulf R Rapp
Journal:  J Biol Chem       Date:  2006-04-07       Impact factor: 5.157

7.  Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.

Authors:  Mark S Cragg; Elisa S Jansen; Michele Cook; Claire Harris; Andreas Strasser; Clare L Scott
Journal:  J Clin Invest       Date:  2008-10-23       Impact factor: 14.808

8.  Grb10 and active Raf-1 kinase promote Bad-dependent cell survival.

Authors:  Sem Kebache; Josée Ash; Matthew G Annis; John Hagan; Maria Huber; Jennifer Hassard; Colin L Stewart; Malcolm Whiteway; André Nantel
Journal:  J Biol Chem       Date:  2007-05-29       Impact factor: 5.157

9.  Mutant B-RAF mediates resistance to anoikis via Bad and Bim.

Authors:  K Boisvert-Adamo; A E Aplin
Journal:  Oncogene       Date:  2008-02-04       Impact factor: 9.867

10.  Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL.

Authors:  Andrew Macdonald; David G Campbell; Rachel Toth; Hilary McLauchlan; C James Hastie; J Simon C Arthur
Journal:  BMC Cell Biol       Date:  2006-01-10       Impact factor: 4.241

View more
  7 in total

1.  Proteogenomic characterization of pancreatic ductal adenocarcinoma.

Authors:  Liwei Cao; Chen Huang; Daniel Cui Zhou; Yingwei Hu; T Mamie Lih; Sara R Savage; Karsten Krug; David J Clark; Michael Schnaubelt; Lijun Chen; Felipe da Veiga Leprevost; Rodrigo Vargas Eguez; Weiming Yang; Jianbo Pan; Bo Wen; Yongchao Dou; Wen Jiang; Yuxing Liao; Zhiao Shi; Nadezhda V Terekhanova; Song Cao; Rita Jui-Hsien Lu; Yize Li; Ruiyang Liu; Houxiang Zhu; Peter Ronning; Yige Wu; Matthew A Wyczalkowski; Hariharan Easwaran; Ludmila Danilova; Arvind Singh Mer; Seungyeul Yoo; Joshua M Wang; Wenke Liu; Benjamin Haibe-Kains; Mathangi Thiagarajan; Scott D Jewell; Galen Hostetter; Chelsea J Newton; Qing Kay Li; Michael H Roehrl; David Fenyö; Pei Wang; Alexey I Nesvizhskii; D R Mani; Gilbert S Omenn; Emily S Boja; Mehdi Mesri; Ana I Robles; Henry Rodriguez; Oliver F Bathe; Daniel W Chan; Ralph H Hruban; Li Ding; Bing Zhang; Hui Zhang
Journal:  Cell       Date:  2021-09-16       Impact factor: 66.850

2.  Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation.

Authors:  Vijay Pandey; Baocheng Wang; Chakrabhavi Dhananjaya Mohan; Ainiah Rushdiana Raquib; Shobith Rangappa; Venkatachalaiah Srinivasa; Julian E Fuchs; Kesturu S Girish; Tao Zhu; Andreas Bender; Lan Ma; Zhinan Yin; Kanchugarakoppal S Rangappa; Peter E Lobie
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-11       Impact factor: 11.205

3.  C-Raf deficiency leads to hearing loss and increased noise susceptibility.

Authors:  Rocío de Iriarte Rodríguez; Marta Magariños; Verena Pfeiffer; Ulf R Rapp; Isabel Varela-Nieto
Journal:  Cell Mol Life Sci       Date:  2015-05-15       Impact factor: 9.261

4.  Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.

Authors:  Valentina Condelli; Francesca Maddalena; Lorenza Sisinni; Giacomo Lettini; Danilo Swann Matassa; Annamaria Piscazzi; Giuseppe Palladino; Maria Rosaria Amoroso; Franca Esposito; Matteo Landriscina
Journal:  Oncotarget       Date:  2015-09-08

5.  Data-derived modeling characterizes plasticity of MAPK signaling in melanoma.

Authors:  Marti Bernardo-Faura; Stefan Massen; Christine S Falk; Nathan R Brady; Roland Eils
Journal:  PLoS Comput Biol       Date:  2014-09-04       Impact factor: 4.475

6.  Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma From Chinese Patients.

Authors:  Lulu Pan; Xijun Wang; Longhai Yang; Lei Zhao; Linhui Zhai; Junyu Xu; Yikun Yang; Yousheng Mao; Shujun Cheng; Ting Xiao; Minjia Tan
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

7.  BAD overexpression inhibits cell growth and induces apoptosis via mitochondrial-dependent pathway in non-small cell lung cancer.

Authors:  Li Jiang; Man Luo; Dan Liu; Bojiang Chen; Wen Zhang; Lin Mai; Jing Zeng; Na Huang; Yi Huang; Xianming Mo; Weimin Li
Journal:  Cancer Cell Int       Date:  2013-06-01       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.